Work

Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw379.29

Authors: M. Davies, J.J. Grob, G.V. Long, K. Flaherty, P. Nathan, A. Ribas, D. Schadendorf, B. Mookerjee, J.J. Legos, S. Lane, C. Robert

Institutions: The University of Texas MD Anderson Cancer Center, Aix-Marseille Université, The University of Sydney, Melanoma Institute Australia, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Mount Vernon Cancer Centre, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Essen University Hospital, Novartis (United States), Institut Gustave Roussy, Fondation Gustave Roussy

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, GlaxoSmithKline, Sanofi, North Carolina GlaxoSmithKline Foundation, Genentech

OpenAlex ID: W2586315561

FWCI:

Cites:

Cited by:

Related to: 10